The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, multicenter phase III trial of bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer.
Suayib Yalcin
Disclosure not yet available
Ruchan Uslu
Disclosure not yet available
Faysal Dane
Disclosure not yet available
Ugur Yilmaz
Disclosure not yet available
Nurullah Zengin
Disclosure not yet available
Evin Buyukunal
Disclosure not yet available
Suleyman Buyukberber
Disclosure not yet available
Celalettin Camci
Disclosure not yet available
Orhan Sencan
Disclosure not yet available
Saadettin Kilickap
Disclosure not yet available